000 | 03216na a2200397 4500 | ||
---|---|---|---|
999 |
_c3221 _d3221 |
||
003 | PC3221 | ||
005 | 20210625062759.0 | ||
008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_aVera, Francisco _92433 _eCirugía Cardiovascular |
||
245 | 0 | 0 |
_aSafety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. _h[artículo] |
260 |
_bHIV clinical trials, _c2013 |
||
300 | _a14(5):204-15. | ||
500 | _aFormato Vancouver: Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P et al. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. | ||
501 | _aPMID: 24144897 | ||
504 | _aContiene 43 referencias | ||
520 | _aOBJECTIVES: Current antiretroviral guidelines state that being older than 50 to 55 years of age is an indication to start antiretroviral therapy (ART), regardless of CD4 status. However, no references to the preferred combination ART (cART) for these patients have been described. Our study compares emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) versus other nucleoside reverse transcriptase inhibitor (NNRTI) regimens in HIV ART-naïve patients who are ≥50 years. | ||
710 |
_9625 _aInstituto de Investigación imas12 |
||
710 |
_9353 _aServicio de Cirugía Cardiovascular |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3221.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |